NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Viking Therapeutics, Inc. (VKTX) Stock Analysis

Viking Therapeutics, Inc. (VKTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VKTX

$34.87

+$0.89 (+2.62%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VKTX with… →

VKTX Key Statistics

As of Sep 4, 2026
Trading
Open
$33.75
Previous Close
$33.98
Day's Range
33.56–34.95
52-Week Range
22.96–43.15
Volume
1.40M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.68
Valuation
Market Cap
$4.07B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.67
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$359.64M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
116.65M
1-Year Return
+31.44%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
2.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VKTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−0.88%
2025−12.57%
2024+116.23%
2023+97.98%
2022+104.35%
2021−18.29%
2020−29.80%
2019+4.84%
2018+88.42%
2017+241.18%
2016 (partial year)−12.50%

As of September 4, 2026.

VKTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$359.64M—
2024$0.00−$109.96M—
2023$0.00−$85.90M—
2022$0.00−$68.87M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$393.34M−$359.64M—
2024$0.00—−$150.92M−$109.96M—
2023$0.00—−$100.83M−$85.90M—
2022$0.00—−$70.36M−$68.87M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VKTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricVKTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Viking Therapeutics, Inc. (VKTX) at $4.07B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 65 employees.

The 52-week range on file runs from $22.96 to $43.15. VKTX last closed at $34.87 on September 4, 2026. That is +$0.89 (+2.62%) against the previous close. The latest close sits 51.88% above that 52-week low.

Financial Health

In fiscal 2025, Viking Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $359.64M. Profit margin runs at 0%. Trailing earnings per share are −4.67.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.68. Daily returns over the trailing 10 years annualize to a volatility of 97.11%. Over the trailing twelve months the price has returned +31.44%. Measured over 10 years, that is +38.42% a year compounded.

Growth & Income

The record shows no dividend for VKTX.

The strongest complete calendar year on file is 2017 at +241.18%; the weakest is 2020 at −29.80%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is −0.88% year to date.

Peer Comparison

Viking Therapeutics, Inc. (VKTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Viking Therapeutics, Inc. VKTX $4.07B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Viking Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Visit website →